Targeted Therapies Do Not Increase Cardiovascular Risk in Psoriasis
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
Diagnosis & Disease Information
Depression, Anxiety Reduce Likelihood of Achieving Minimal Disease Activity in PsA
Researchers determined the effect of depression and anxiety on disease activity among patients with psoriatic arthritis.
Stelara Approved for Pediatric Psoriatic Arthritis
The approval is supported by evidence from adequate and well-controlled studies of Stelara.
FDA to Review Abrilada for Interchangeability With Humira
The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid arthritis.
Is There a Link Between Psoriatic Arthritis and All-Cause Mortality?
In a population-based study, researchers examined the association between psoriatic arthritis and all-cause mortality and leading causes of death.
Does TNFi Therapy for Psoriatic Arthritis Affect COVID-19 Vaccine Immunogenicity?
Researchers studied the immune response to COVID-19 vaccination in patients with psoriatic arthritis receiving treatment with tumor necrosis factor inhibitors.
Presence of Psoriatic Arthritis Associated With Depression in Patients With Psoriasis
Researchers determined the association of depression and suicidal ideation with psoriatic arthritis in patients with psoriasis, and assessed whether this association was independent of other comorbidities.
Skyrizi Gets FDA Approval for Psoriatic Arthritis
The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or nonbiologic DMARDs.
Yusimry, a Humira Biosimilar Product, Gets FDA Approval
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Rinvoq Approved for Active Psoriatic Arthritis
The application is supported by data from two phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2) that assessed upadacitinib in adults with active PsA.
- Loading...
Loading...
Next post in News
Loading... 
Loading...